drugset
drugset / Trial / NCT05556863

Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

NCT05556863 ↗

Phase 1 Completed 91 enrolled Electra Therapeutics Inc.
RandomizedSequentialTriple-blindOther

Summary

ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.

Timeline

Start
2021-10-18
Primary completion
2023-11-20
Completion
2023-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ELA026 Monoclonal antibody 0.001 mg/kg Intravenous

Indications

No indication recorded.